Fig. 10. Rs764932023 in MYO9B gene is associated with T1D in humans.

a–e MoDCs were differentiated from PBMCs of T1D patients carrying the MYO9B^R133Q polymorphism or not, and subjected to the following experiments. n = 3 per genotype. a ECAR of MoDCs stimulated with LPS for 24 h. b Accordingly, baseline glycolysis, maximal glycolytic capacity, and glycolytic reserve were shown. c Representative histograms and quantitative data of HLA-DR expression in MoDCs treated with vehicle or LPS for 24 h. d RT-PCR analysis of relative mRNA expression of cytokines in MoDCs stimulated with LPS for 8 h. e Proliferation of CFSE-labeled allogenic CD4⁺ T cells incubated with MoDCs derived from MYO9B^R133Q carriers and non-carriers. f ECAR of Myo9b deficient mouse DCs transduced with adenoviral particles containing vector, MYO9B^WT, or MYO9B^R133Q, and then stimulated with LPS for 24 h. g Baseline glycolysis and maximal glycolytic capacity in cells as shown in f. h Expression of MHC II of Myo9b deficient mouse DCs transduced with vector, MYO9B^WT, or MYO9B^R133Q adenovirus and then stimulated with LPS for 24 h. i RT-PCR analysis of relative mRNA expression of proinflammatory cytokine genes in Myo9b deficient mouse DCs transduced with vector, MYO9B^WT, or MYO9B^R133Q adenovirus and then stimulated with LPS for 8 h. j Migration of Myo9b^−/− mouse DCs transduced with vector, MYO9B^WT, or MYO9B^R133Q virus and then stimulated with LPS for 18 h, analyzed by transwell assay. Scale bars: 100 μm. Original magnification: ×200. k Mouse DCs deficient in Myo9b were transduced with vector, MYO9B^WT, or MYO9B^R133Q virus. Shown is the proliferation of CFSE-labeled BDC2.5 naive CD4⁺ T cells incubated with BDC2.5 mimotope-pulsed DCs. Data were collected from three independent experiments (f–k). Values are expressed as mean ± SEM. Statistical difference in b–e was assessed using unpaired two-sided Student’s t test; in g–k was analyzed by one-way ANOVA.